3/23
10:57 am
mltx
Rating for MLTX
Low
Report
Rating for MLTX
3/23
10:57 am
mltx
Rating for MLTX
Low
Report
Rating for MLTX
3/23
08:42 am
mltx
MoonLake Immunotherapeutics (MLTX) was upgraded by Wolfe Research from "underperform" to "outperform". They now have a $24.00 price target on the stock.
Low
Report
MoonLake Immunotherapeutics (MLTX) was upgraded by Wolfe Research from "underperform" to "outperform". They now have a $24.00 price target on the stock.
3/23
08:42 am
mltx
MoonLake Immunotherapeutics (MLTX) was upgraded by Wolfe Research from "underperform" to "outperform". They now have a $24.00 price target on the stock.
Low
Report
MoonLake Immunotherapeutics (MLTX) was upgraded by Wolfe Research from "underperform" to "outperform". They now have a $24.00 price target on the stock.
3/23
05:43 am
mltx
MoonLake upgraded to Outperform from Underperform at Wolfe Research
Low
Report
MoonLake upgraded to Outperform from Underperform at Wolfe Research
3/23
05:43 am
mltx
MoonLake upgraded to Outperform from Underperform at Wolfe Research
Low
Report
MoonLake upgraded to Outperform from Underperform at Wolfe Research
3/2
11:31 am
mltx
Rating for MLTX
Low
Report
Rating for MLTX
3/2
11:31 am
mltx
Rating for MLTX
Low
Report
Rating for MLTX
2/26
06:13 am
mltx
Rating for MLTX
Low
Report
Rating for MLTX
2/26
06:13 am
mltx
Rating for MLTX
Low
Report
Rating for MLTX
2/24
09:39 am
mltx
Rating for MLTX
Low
Report
Rating for MLTX
2/24
09:39 am
mltx
Rating for MLTX
Low
Report
Rating for MLTX
2/24
08:02 am
mltx
MoonLake Immunotherapeutics (NASDAQ:MLTX) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
Medium
Report
MoonLake Immunotherapeutics (NASDAQ:MLTX) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
2/20
09:32 am
mltx
Rating for MLTX
Medium
Report
Rating for MLTX
2/20
09:32 am
mltx
Rating for MLTX
Medium
Report
Rating for MLTX
2/9
12:27 pm
mltx
MoonLake Immunotherapeutics (NASDAQ:MLTX) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $24.00 price target on the stock.
Low
Report
MoonLake Immunotherapeutics (NASDAQ:MLTX) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $24.00 price target on the stock.
2/9
11:48 am
mltx
Rating for MLTX
Low
Report
Rating for MLTX
2/3
08:12 am
mltx
MoonLake Immunotherapeutics (NASDAQ:MLTX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
Medium
Report
MoonLake Immunotherapeutics (NASDAQ:MLTX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
1/15
04:19 am
mltx
Rating for MLTX
Medium
Report
Rating for MLTX
1/15
04:19 am
mltx
Rating for MLTX
Medium
Report
Rating for MLTX
1/15
04:19 am
mltx
Rating for MLTX
Medium
Report
Rating for MLTX
1/14
05:09 pm
mltx
MoonLake Immunotherapeutics downgraded to Sell from Neutral at Goldman Sachs
Medium
Report
MoonLake Immunotherapeutics downgraded to Sell from Neutral at Goldman Sachs
1/14
05:09 pm
mltx
MoonLake Immunotherapeutics downgraded to Sell from Neutral at Goldman Sachs
Medium
Report
MoonLake Immunotherapeutics downgraded to Sell from Neutral at Goldman Sachs
1/14
05:09 pm
mltx
MoonLake Immunotherapeutics downgraded to Sell from Neutral at Goldman Sachs
Medium
Report
MoonLake Immunotherapeutics downgraded to Sell from Neutral at Goldman Sachs
1/9
08:02 am
mltx
MoonLake Immunotherapeutics (NASDAQ:MLTX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock, up previously from $26.00.
High
Report
MoonLake Immunotherapeutics (NASDAQ:MLTX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock, up previously from $26.00.